Research

Metal attenuating therapies in neurodegenerative disease


Reference:

Mot, A. I., Wedd, A. G., Sinclair, L., Brown, D. R., Collins, S. J. and Brazier, M. W., 2011. Metal attenuating therapies in neurodegenerative disease. Expert Review of Neurotherapeutics, 11 (12), pp. 1717-1745.

Related documents:

This repository does not currently have the full-text of this item.
You may be able to access a copy if URLs are provided below. (Contact Author)

Official URL:

http://dx.doi.org/10.1586/ern.11.170

Abstract

The clinical and pathological spectrum of neurodegenerative diseases is diverse, although common to many of these disorders is the accumulation of misfolded proteins, with oxidative stress thought to be an important contributing mechanism to neuronal damage. As a corollary, transition metal ion dyshomeostasis appears to play a key pathogenic role in a number of these maladies, including the most common of neurodegenerative diseases. In this review, studies spanning a wide variety of neurodegenerative disorders are presented with their involvement of transition metals compared and contrasted, including more detailed treatise in relation to Alzheimer's disease, Parkinson's disease and prion diseases. For each of these diseases, a discussion of the evolving scientific rationale for the development of therapies aimed at ameliorating the detrimental effects of transition metal dysregulation, including results from various human trials, is then provided.

Details

Item Type Articles
CreatorsMot, A. I., Wedd, A. G., Sinclair, L., Brown, D. R., Collins, S. J. and Brazier, M. W.
DOI10.1586/ern.11.170
Uncontrolled Keywordsclioquinol, prion, pbt2, chelator, copper, parkinson's disease, alzheimer's disease, manganese, oxidative stress, amyloid, brain, hydroxyl radical, mpac
DepartmentsFaculty of Science > Biology & Biochemistry
RefereedYes
StatusPublished
ID Code28739

Export

Actions (login required)

View Item